Literature DB >> 7065792

Chemical hyperthyroidism: serum triiodothyronine levels in clinically euthyroid individuals treated with levothyroxine.

D Salmon, M Rendell, J Williams, C Smith, D A Ross, J M Waud, J E Howard.   

Abstract

We have observed many patients treated with levothyroxine sodium who have elevated serum thyroxine (T4) levels but appear clinically euthyroid. Such patients generally have normal serum triiodothyronine (T3) values. A retrospective review at The Johns Hopkins Hospital, Baltimore, comparing the correlation of T3 and T4 values in levothyroxine-treated patients with that in patients not so treated was carried out from 1977 to 1979. Mean free thyroxine index (FTI) value in 104 levothyroxine-treated patients was 4.70 +/- 0.2 and mean T3 value was 177 +/- 9 ng/dL. In a group of 50 hyperthyroid patients, mean FTI value was 7.26. +/- 0.5, with a mean T3 value of 389 +/- 26 ng/dL. In 71 euthyroid patients, mean FTI value was 2.36 +/- 0.1, with a T3 value of 137 +/- 3 ng/dL. Computed ratios of T3 to FTI and T3 to T4 were significantly lower in the group treated with levothyroxine than in either the hyperthyroid or euthyroid nontreated groups. Levothyroxine-treated patients with high T4 levels but normal T3 levels were clinically euthyroid. Patients not treated with levothyroxine with similarly elevated T4 levels had elevated T3 levels and were clinically hyperthyroid. It is concluded that lower relative T3 levels in levothyroxine-treated patients may explain why these patients appear clinically euthyroid despite elevated T4 values. Serum T3 determination is the procedure of choice for evaluation of levothyroxine-treated individuals. Furthermore, an elevated FTI value in such an individual does not, in itself, dictate need to reduce dosage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065792     DOI: 10.1001/archinte.142.3.571

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism.

Authors:  James E Haddow; Louis M Neveux; Glenn E Palomaki; Geralyn Lambert-Messerlian; Fergal D Malone; Mary E D'Alton
Journal:  Thyroid       Date:  2015-06-23       Impact factor: 6.568

2.  Thyroid hormone replacement.

Authors:  R Cygan; L Rucker
Journal:  West J Med       Date:  1983-08

Review 3.  Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?

Authors:  Matthew D Ettleson; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

4.  Suppression of peripheral blood natural killer cell activity by excess thyroid hormone.

Authors:  M Papic; J Stein-Streilein; M Zakarija; J M McKenzie; J Guffee; M A Fletcher
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy.

Authors:  L Bartalena; E Martino; M Falcone; A Pacchiarotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

6.  Systemic Thyroid Hormone Status in Treated Graves' Disease.

Authors:  Fereidoun Azizi; Atieh Amouzegar; Maryam Tohidi; Mehdi Hedayati; Leila Cheraghi; Yadollah Mehrabi
Journal:  Int J Endocrinol Metab       Date:  2019-10-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.